JP2016509601A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016509601A5 JP2016509601A5 JP2015555167A JP2015555167A JP2016509601A5 JP 2016509601 A5 JP2016509601 A5 JP 2016509601A5 JP 2015555167 A JP2015555167 A JP 2015555167A JP 2015555167 A JP2015555167 A JP 2015555167A JP 2016509601 A5 JP2016509601 A5 JP 2016509601A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- patient
- effective amount
- compound according
- motomeko
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 42
- 239000008194 pharmaceutical composition Substances 0.000 claims description 10
- 208000020084 Bone disease Diseases 0.000 claims description 8
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical group [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 8
- 229910052739 hydrogen Inorganic materials 0.000 claims description 8
- 239000001257 hydrogen Substances 0.000 claims description 8
- 230000002401 inhibitory effect Effects 0.000 claims description 8
- 208000017520 skin disease Diseases 0.000 claims description 8
- 208000005770 Secondary Hyperparathyroidism Diseases 0.000 claims description 6
- 208000013725 Chronic Kidney Disease-Mineral and Bone disease Diseases 0.000 claims description 5
- 210000004027 cell Anatomy 0.000 claims description 5
- 230000002062 proliferating effect Effects 0.000 claims description 5
- 201000006409 renal osteodystrophy Diseases 0.000 claims description 5
- AEDMQUAPBVOJNN-UHFFFAOYSA-N [3-[2-[4-[2-(trifluoromethyl)phenoxy]piperidin-1-yl]-1,3-thiazol-5-yl]-1,2,4-oxadiazol-5-yl]methanol Chemical compound O1C(CO)=NC(C=2SC(=NC=2)N2CCC(CC2)OC=2C(=CC=CC=2)C(F)(F)F)=N1 AEDMQUAPBVOJNN-UHFFFAOYSA-N 0.000 claims description 4
- 210000001789 adipocyte Anatomy 0.000 claims description 4
- 230000037118 bone strength Effects 0.000 claims description 4
- 230000004069 differentiation Effects 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 108090000623 proteins and genes Proteins 0.000 claims description 4
- 238000013518 transcription Methods 0.000 claims description 4
- 230000035897 transcription Effects 0.000 claims description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 2
- 125000006239 protecting group Chemical group 0.000 claims description 2
- ILMRJRBKQSSXGY-UHFFFAOYSA-N tert-butyl(dimethyl)silicon Chemical group C[Si](C)C(C)(C)C ILMRJRBKQSSXGY-UHFFFAOYSA-N 0.000 claims description 2
- -1 triethylsilyl Chemical group 0.000 claims description 2
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 claims 2
- 238000000034 method Methods 0.000 description 19
- 208000008589 Obesity Diseases 0.000 description 3
- 210000000577 adipose tissue Anatomy 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 235000020824 obesity Nutrition 0.000 description 3
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361755702P | 2013-01-23 | 2013-01-23 | |
| US61/755,702 | 2013-01-23 | ||
| US14/084,281 | 2013-11-19 | ||
| US14/084,281 US9416102B2 (en) | 2013-01-23 | 2013-11-19 | (22E)-2-methylene-22-dehydro-1α,24,25-trihydroxy-19-nor-vitamin D3 analogs |
| PCT/US2013/077486 WO2014116386A1 (en) | 2013-01-23 | 2013-12-23 | (22E)-2-METHYLENE-22-DEHYDRO-1α,24,25-TRIHYDROXY-19-NOR-VITAMIN D3 ANALOGS |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016509601A JP2016509601A (ja) | 2016-03-31 |
| JP2016509601A5 true JP2016509601A5 (enExample) | 2017-01-05 |
| JP6383365B2 JP6383365B2 (ja) | 2018-08-29 |
Family
ID=51208161
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015555167A Expired - Fee Related JP6383365B2 (ja) | 2013-01-23 | 2013-12-23 | （２２Ｅ）−２−メチレン−２２−デヒドロ−１α，２４，２５−トリヒドロキシ−１９−ノル−ビタミンＤ３類似体 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US9416102B2 (enExample) |
| EP (1) | EP2951152B1 (enExample) |
| JP (1) | JP6383365B2 (enExample) |
| AU (1) | AU2013375208B2 (enExample) |
| CA (1) | CA2897527C (enExample) |
| WO (1) | WO2014116386A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2144872A2 (en) * | 2007-04-18 | 2010-01-20 | Johns Hopkins University | Low calcemic, highly antiproliferative, analogs of calcitriol |
| JP2019533022A (ja) | 2016-10-24 | 2019-11-14 | ユマニティ セラピューティクス，インコーポレーテッド | 化合物及びその使用 |
| EP3566055B1 (en) | 2017-01-06 | 2025-03-12 | Janssen Pharmaceutica NV | Scd inhibitor for the treatment of neurological disorders |
| JP2020537664A (ja) * | 2017-10-17 | 2020-12-24 | ウィスコンシン アラムニ リサーチ ファンデーション | （２２Ｅ）−（２４Ｒ）−２−メチレン−２２−デヒドロ−１α，２４，２５−トリヒドロキシ−１９−ノル−ビタミンＤ３の結晶化手順 |
| CA3083000A1 (en) | 2017-10-24 | 2019-05-02 | Yumanity Therapeutics, Inc. | Compounds and uses thereof |
| CN116103348A (zh) * | 2018-03-16 | 2023-05-12 | 江苏瑞科医药科技有限公司 | 六氢呋喃并呋喃醇衍生物的制备方法、其中间体及其制备方法 |
| WO2019183587A1 (en) | 2018-03-23 | 2019-09-26 | Yumanity Therapeutics, Inc. | Compounds and uses thereof |
| WO2020154571A1 (en) | 2019-01-24 | 2020-07-30 | Yumanity Therapeutics, Inc. | Compounds and uses thereof |
| EA202192047A1 (ru) | 2019-11-13 | 2021-12-08 | Юманити Терапьютикс, Инк. | Соединения и их применение |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5086191A (en) | 1991-05-28 | 1992-02-04 | Wisconsin Alumni Research Foundation | Intermediates for the synthesis of 19-nor vitamin D compounds |
| JP3722832B2 (ja) * | 1992-06-22 | 2005-11-30 | ルーナー、コーポレーション | 経口用１α−ヒドロキシプレビタミンＤ |
| GB9214202D0 (en) | 1992-07-03 | 1992-08-12 | Leo Pharm Prod Ltd | Chemical compounds |
| DE69400495T2 (de) | 1993-04-05 | 1997-04-30 | Wisconsin Alumni Res Found | 19-Nor-vitamin-D3-Verbindung mit einem Substituent an die 2. Stelle |
| DK0717034T3 (da) | 1994-12-14 | 1999-10-18 | Duphar Int Res | Vitamin D-forbindelser og fremgangsmåde til fremstilling af disse forbindelser |
| US6242434B1 (en) * | 1997-08-08 | 2001-06-05 | Bone Care International, Inc. | 24-hydroxyvitamin D, analogs and uses thereof |
| US5945410A (en) | 1997-03-17 | 1999-08-31 | Wisconsin Alumni Research Foundation | 2-alkyl-19-nor-vitamin D compounds |
| US5843928A (en) | 1997-03-17 | 1998-12-01 | Wisconsin Alumni Research Foundation | 2-alkylidene-19-nor-vitamin D compounds |
| AU743514B2 (en) * | 1997-05-16 | 2002-01-24 | Women & Infants Hospital | Cyclic ether vitamin D3 compounds, 1alpha (OH) 3-EPI-vitamin D3 compounds and uses thereof |
| GB9721156D0 (en) | 1997-10-06 | 1997-12-03 | Leo Pharm Prod Ltd | Novel vitamin d analogues |
| WO2002020021A1 (en) | 2000-09-08 | 2002-03-14 | Wisconsin Alumni Research Foundation | 1alpha-hydroxy-2-methylene-19-nor-homopregnacalciferol and its therapeutic applications |
| US6627622B2 (en) | 2002-02-18 | 2003-09-30 | Wisconsin Alumni Research Foundation | (20S)-1α-hydroxy-2-methylene-19-nor-bishomopregnacalciferol and its uses |
| US6566352B1 (en) | 2002-02-18 | 2003-05-20 | Wisconsin Alumni Research Foudation | 1 α-hydroxy-2-methylene-19-nor-pregnacalciferol and its uses |
| AU2004266706B2 (en) | 2003-08-20 | 2009-07-30 | Wisconsin Alumni Research Foundation | 2-methylene-19-nor-vitamin D2 compounds |
| CA2544502A1 (en) | 2003-11-25 | 2005-06-09 | Wisconsin Alumni Research Foundation | Vitamin d analogs for obesity prevention and treatment |
| US8404667B2 (en) | 2006-12-29 | 2013-03-26 | Wisconsin Alumni Research Foundation | Compounds, compositions, kits and methods of use to orally and topically treat acne and other skin conditions by 19-Nor vitamin D analog |
| US9221753B2 (en) * | 2004-02-03 | 2015-12-29 | Chugai Seiyaku Kabushiki Kaisha | Process for the synthesis of vitamin D compounds and intermediates for the synthesis of the compounds |
-
2013
- 2013-11-19 US US14/084,281 patent/US9416102B2/en not_active Expired - Fee Related
- 2013-12-23 CA CA2897527A patent/CA2897527C/en active Active
- 2013-12-23 JP JP2015555167A patent/JP6383365B2/ja not_active Expired - Fee Related
- 2013-12-23 AU AU2013375208A patent/AU2013375208B2/en not_active Ceased
- 2013-12-23 EP EP13824060.1A patent/EP2951152B1/en not_active Not-in-force
- 2013-12-23 WO PCT/US2013/077486 patent/WO2014116386A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016509601A5 (enExample) | ||
| BR112012019374A2 (pt) | composição farmacêutica, pellet de liberação prolongada, composição farmacêutica oral, método para tratamento de uma doença neurodegenerativa ou um dano ao sistema nervoso em um indivíduo necessitado do mesmo e método para preparação de uma formulação de liberação prolongada de um agente ativo | |
| FI3504187T3 (fi) | Pridopidiinin käyttö toiminnallisen heikkenemisen hoitoa varten | |
| WO2011044506A3 (en) | Sulphone compounds for use in the treatment of obesity | |
| HK1206246A1 (en) | Use of high dose laquinimod for treating multiple sclerosis | |
| JP2013509441A5 (enExample) | ||
| JP2015501783A5 (enExample) | ||
| PH12012501480A1 (en) | Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof | |
| EA201491606A1 (ru) | Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения | |
| PH12015502691A1 (en) | Use of high dose pridopidine for treating huntington's disease | |
| JP2013507415A5 (enExample) | ||
| JP2016525102A5 (enExample) | ||
| PH12013501193A1 (en) | Use of laquinimod for reducing fatigue, improving functional status, and improving quality of life in multiple sclerosis patients | |
| HK1211525A1 (en) | Laquinimod and pridopidine for treating neurodegenerative disorders | |
| NO20100301L (no) | Forbedrete brimonidinsammensetninger for behandling av erytem | |
| NZ700195A (en) | Compositions comprising deoxycholic acid | |
| JP2017511377A5 (enExample) | ||
| MX2014014969A (es) | Combinacion de un inhibidor de la 17-alfa-hidroxilasa (c17,20-liasa) y un inhibidor especifico de la pi-3k para tratar una enfermedad tumoral. | |
| WO2012098562A3 (en) | Liquid oral compositions of lanthanum salts | |
| WO2013061004A8 (fr) | Nouveaux composés di-substitués de la diamino-3,4-cyclobutène-3-dione-1,2 utiles dans le traitement de pathologies médiées par des chimiokines | |
| WO2014078575A3 (en) | Novel orally bioavailable breathing control modulating compounds, and methods of using same | |
| JP2015502926A5 (enExample) | ||
| EP3309555A3 (en) | Methods for preventing or treating disorders by increasing bioavailability of iron and related pharmaceutical formulation | |
| JP2015509075A5 (enExample) | ||
| PH12018502445A1 (en) | Compositions and methods for treating negative symptoms in non-schizophrenic patients |